Skip to main content

PDE5 Inhibitors and their Applications

Buy Article:

$55.00 plus tax (Refund Policy)

PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides cAMP and cGMP to the corresponding 5-nucleoside monophosphate.

PDE5 takes part in many physiological and pathological functions, therefore selective PDE5 inhibitors are potentially useful for a variety of pathologies. At the present, PDE5 inhibitors available on the market have been used for the treatment of erectile dysfunction but, at the same time, are in clinical trials investigating other pathologies such as pulmonary arterial hypertension, coronary vasospasm, benign prostatic hyperplasia etc. This review analyzes the PDE5 inhibitors currently in clinical use, the drugs in clinical trials and the most representative chemical classes published in literature in this last decade.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Phosphodiesterase 5 (PDE5); selectivity; therapeutic applications

Document Type: Research Article

Affiliations: Dipartimento di Scienze Farmaceutiche, Via Ugo Schiff 6, Sesto Fiorentino 50019 Firenze, Italy.

Publication date: 2010-08-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more